Open AccessA clinical case of the effective combined use of BCL-2 and PI3K inhibitors in the treatment of a patient with an unfavorable chronic lymphocytic leukemia with transformation into diffuse large B-cell lymphoma (Richter’s syndrome)
Author(s) -
O. A. Rukavitsyn,
V. P. Pop,
M. V. Drozd,
Yu. E. Ryabukhina
Publication year - 2022
Publication title -
onkogematologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.118
H-Index - 3
eISSN - 2413-4023
pISSN - 1818-8346
DOI - 10.17650/1818-8346-2022-17-4-38-47
Subject(s) - chronic lymphocytic leukemia , venetoclax , medicine , lymphoma , clinical trial , oncology , ibrutinib , diffuse large b cell lymphoma , pathogenesis , aggressive lymphoma , leukemia , cancer research , rituximab